Member Info for Beamer21

Barclays increased to 8.6% on 1st April

Last updated 31/12/19 and I bet they’ve increased since then along with Barclays

https://urbanexposureplc.com/investors/aim-rule-26/significant-shareholders/

However it was earlier proposed that they would issue a distribution circa 73p if they went ahead with the delist

Barclays increased from below threshold to 8.6% on 1st April

The Diggles are connected all over the place through Vulpes including the Jenner Institute vaccine consortium through Oxford BioMedica

Wondering as they’re spun out of oxford university if they’re playing a role in the remap cap and Revovery trials and research

I was just looking too.... interesting work with biomarkers

A quick flick through recent RNS’s will tell you all you need to know

Final results released just this week and some blockbuster contracts with the NHS

Newboy - personally think that we have been seeing selling from shareholders who’s lock in agreements have just expired

Very nice update this morning

From 10/4

Mark Stevenson on Thursday told the BBC’s Today programme the company had agreed with the government to supply “more than 100,000 tests per day” and would scale up its manufacturing capacity to enable the kits to be manufactured in the UK. 

It appears that Mark Street-Docherty left Elucigene in Jan 2020 and has set up SD Life Science Consulting - maybe he might need some funds for his new venture?

lock in agreements from the Elucigene acquisition expiring next week? Makes me wonder of somehow they might have been forward sold

I use Interactive Investor for trading US stocks and Investors hub part of ADVFN for Nasdaq Level 2 etc

Seems a bit premature of HL though

So under the radar it seems

Steve, you clearly have patience and with FY20 expected to come in close to £17m I think your patience will be rewarded

Plenty of other catalysts too to loom forward to including the additional revenues from COVID19

Trading update issued last year on 9th April so one likely to drop any time

Should be good as plenty of news to report on in addition to positive FY20 figures

Outlook form half year report issued 2nd December 2019 - pre COVID19 and NCYT agreement

FY20 revenues coming in close to £17m circa £8.9m FY19

Outlook

I am delighted with the transformation of the business and that the strong foundation we've established for delivering rapid growth is already delivering results. At this interim stage we are firmly on target to deliver full year results in-line with market expectations, with consensus analyst forecasts looking for revenues of nearly £17m for the year ending 31 March 2020, a considerable jump from last year's £8.9m.



I am very excited about the significant opportunity ahead of us. We have first-class products that are leading the way in the growing genetic testing market. Our IONA® test has strong reputation for reliability and accuracy and was the first CE marked NIPT product for the European Market. We are also in a position to offer our test across all sequencing platforms and we believe that the launch of the IONA® test on the Illumina platform will be a strong driver of growth next year.

We have established a significant commercial footprint and now sell into 60 territories and we are certain that we will quickly benefit from selling a wider range of products into a wider range of markets, and this in turn will be reflected in further shareholder value creation. We also expect to leverage our strong technical capabilities to develop more content, offering additional products and services to more customers as the adoption of genetic testing becomes more widespread.

We remain confident in our outlook for the year end and very excited about the prospects for further growth over the following years.

Expecting lab testing news on behalf of NHS too

Very good news for YGEN